EGFR-
8 drugsPredictive biomarker for patient selection in 41 indications
8
Approved Drugs
41
Indications
7
Companies
EGFR- is a precision-medicine biomarker linked to 8 FDA-approved targeted drugs from 7 companies, spanning 41 indications including Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing EGFR- drugs below.
Search EGFR- Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting EGFR-
| Drug | Company | Therapeutic Area |
|---|---|---|
| ALIMTA | Eli Lilly | Oncology |
| KEYTRUDA | Merck | Oncology |
| LIBTAYO | Regeneron | Oncology |
| OPDIVO QVANTIG | Bristol-Myers Squibb | Oncology |
| PEMETREXED DISODIUM | Apotex | Oncology |
| PEMFEXY | EAGLE PHARMS | Oncology |
| TECENTRIQ | Roche | Oncology |
| YERVOY | Bristol-Myers Squibb | Oncology |
EGFR- Indications
Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer Renal Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Urothelial Carcinoma Colorectal Cancer Esophageal Cancer Gastroesophageal Junction Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Esophageal Adenocarcinoma Cutaneous Melanoma Microsatellite Instability-High Cancer Mismatch Repair Deficient Cancer Metastatic cutaneous squamous cell carcinoma Locally advanced cutaneous squamous cell carcinoma Adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation Locally advanced basal cell carcinoma Metastatic basal cell carcinoma First-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with platinum-based chemotherapy First-line monotherapy for locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression (TPS ≥50%) Head and Neck Squamous Cell Cancer Classical Hodgkin Lymphoma Primary Mediastinal Large B-Cell Lymphoma Urothelial Cancer Gastroesophageal Junction Adenocarcinoma Cervical Cancer Biliary Tract Cancer Merkel Cell Carcinoma Endometrial Carcinoma Tumor Mutational Burden-High Cancer Cutaneous Squamous Cell Carcinoma Triple-Negative Breast Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer